Trial Profile

A bioequivalence study of Once-Daily Relexxii to twice daily dosing of Concerta (methylphenidate HCI) 36-mg tablets for the treatment of Attention Deficit Hyperactivity Disorder (ADHD)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 24 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 Dec 2023 New trial record
19 Dec 2023 According to an Alora Pharmaceuticals media release, the company announced the commercial availability of Relexxii (methylphenidate hydrochloride extended-release tablets). Relexxii a once-daily central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults (up to the age of 65 years) and in pediatric patients 6 years of age and older.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com